M
Masataka Harada
Researcher at Takeda Pharmaceutical Company
Publications - 34
Citations - 3839
Masataka Harada is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Peptide sequence & Receptor. The author has an hindex of 16, co-authored 34 publications receiving 3521 citations.
Papers
More filters
Journal ArticleDOI
Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40.
Yasuaki Itoh,Yuji Kawamata,Masataka Harada,Makoto Kobayashi,Ryo Fujii,Shoji Fukusumi,Kazuhiro Ogi,Masaki Hosoya,Yasuhiro Tanaka,Hiroshi Uejima,Hideyuki Tanaka,Minoru Maruyama,Rie Satoh,Shoichi Okubo,Hideki Kizawa,Hidetoshi Komatsu,Fumika Matsumura,Yuko Noguchi,Tokuyuki Shinohara,Shuji Hinuma,Yukio Fujisawa,Masahiko Fujino +21 more
TL;DR: It is shown that a G-protein-coupled receptor, GPR40, which is abundantly expressed in the pancreas, functions as a receptor for long-chain FFAs, and that long- Chain FFAs amplify glucose-stimulated insulin secretion from pancreatic β cells by activating GPR 40.
Journal ArticleDOI
A G Protein-coupled Receptor Responsive to Bile Acids
Yuji Kawamata,Ryo Fujii,Masaki Hosoya,Masataka Harada,Hiromi Yoshida,Masanori Miwa,Shoji Fukusumi,Yugo Habata,Takashi Itoh,Yasushi Shintani,Shuji Hinuma,Yukio Fujisawa,Masahiko Fujino +12 more
TL;DR: It is found that a novel G protein-coupled receptor, TGR5, is responsive to bile acids as a cell-surface receptor, and was abundantly expressed in monocytes/macrophages in human and rabbit.
Journal ArticleDOI
Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
Satoshi Sasaki,Nobuo Cho,Yoshi Nara,Masataka Harada,Satoshi Endo,Nobuhiro Suzuki,Shuichi Furuya,Masahiko Fujino +7 more
TL;DR: The design and synthesis of a series of thieno[2,3-d]pyrimidine-2,4-dione derivatives containing a biaryl moiety led to the discovery of a highly potent and orally active non-peptide LHRH antagonist, compound 9k, which has been selected as a candidate for clinical trials and is expected to provide a new class of potential therapeutic agents for the clinical treatment of a variety of sex-hormone-dependent diseases.
Journal ArticleDOI
Identification of a G Protein-coupled Receptor Specifically Responsive to β-Alanine
Tokuyuki Shinohara,Masataka Harada,Kazuhiro Ogi,Minoru Maruyama,Ryo Fujii,Hideyuki Tanaka,Shoji Fukusumi,Hidetoshi Komatsu,Masaki Hosoya,Yuko Noguchi,Takuya Watanabe,Takeo Moriya,Yasuaki Itoh,Shuji Hinuma +13 more
TL;DR: TGR7 functioned as a specific membrane receptor for β-alanine, suggesting that TGR7 participates in the modulation of neuropathic pain.
Journal ArticleDOI
Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor
Nobuo Cho,Masataka Harada,Toshihiro Imaeda,Takashi Imada,Hirokazu Matsumoto,Yoji Hayase,Satoshi Sasaki,Shuichi Furuya,Nobuhiro Suzuki,Shoichi Okubo,Kazuhiro Ogi,Satoshi Endo,Haruo Onda,Masahiko Fujino +13 more